Financials in USD. Standardized financial statements.
A compact view of how Gemina Laboratories Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue? | $21,502 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $37,506 | $113,239 | $93,368 | $50,282 | $43,834 | $12,090 |
| Gross Profit? | -$16,004 | -$113,239 | -$93,368 | -$50,282 | -$43,834 | -$12,090 |
| Gross Margin? | -74.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $2.22M | $3.80M | $5.09M | $5.98M | $4.73M | $633,507 |
| Operating Income? | -$2.24M | -$3.91M | -$5.09M | -$5.98M | -$4.73M | -$645,600 |
| EBITDA? | -$2.20M | -$3.80M | -$5.18M | -$5.93M | -$4.69M | -$633,510 |
| Income Before Tax | -$2.34M | -$4.07M | -$5.22M | -$5.98M | -$4.73M | -$834,153 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$2.34M | -$4.07M | -$5.22M | -$5.98M | -$4.73M | -$834,153 |
| EPS? | $-0.03 | $-0.06 | $-0.07 | $-0.10 | $-0.10 | $-0.02 |
| Diluted EPS? | $-0.03 | $-0.06 | $-0.07 | $-0.10 | $-0.10 | $-0.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality